2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-170515
    RNF5 agonist 1 69909-92-8
    RNF5 agonist 1 (analog-1), a structural analog of RNF5 inhibitor inh-02 (HY-123967), is a potent RNF5 agonist. RNF5 agonist 1 increases the ubiquitylation status of ATG4B in F508del-CFTR-expressing CFBE41o- cells.
    RNF5 agonist 1
  • HY-170516
    GLP-1 receptor agonist 16 2902596-52-3
    GLP-1 receptor agonist 16 (Example 53) is a GLP-1 agonist. GLP-1 receptor agonist 16 can be used for the research of diabetes, obesity, or nonalcoholic steatohepatitis-related diseases[1].
    GLP-1 receptor agonist 16
  • HY-170522
    ISM012-042
    ISM012-042 is an orally active PHD1 and PHD2 inhibitor with IC50 values of 1.9 and 2.5 nM, respectively. ISM012-042 (2.5 μM) can protect Caco-2 cells from DSS-induced barrier disruption. In lipopolysaccharide (LPS)-induced mouse bone marrow-derived dendritic cells (BMDC), ISM012-042 has anti-inflammatory effects and can dose-dependently reduce the expression of IL-12 subunit IL-12p35 and TNF. ISM012-042 restores intestinal barrier function and alleviates intestinal inflammation in various experimental colitis models. ISM012-042 can be used for intestinal mucosal repair and research into immune diseases.
    ISM012-042
  • HY-170525
    CD73-IN-19 333329-22-9
    CD73-IN-19 (Compound 4ab) is a CD73 inhibitor (with a 44% inhibition rate of CD73 enzymatic activity at 100 μM). CD73-IN-19 (at 10 μM and 100 μM) can completely antagonize the blockade of T cell proliferation induced by TCR (T cell receptor) triggering (which is induced by CD73 activity), and it can also inhibit the hA2A receptor activity in HEK-293 cells (Ki is 3.31 μM). CD73-IN-19 holds promise for research in the field of immune diseases.
    CD73-IN-19
  • HY-170529
    NLRP3-IN-61 3060585-94-3
    NLRP3-IN-61 (Compound 1) is an inhibitor for NLRP3. NLRP3-IN-61 inhibits pyroptosis in THP-1 cell with an IC50 of 12.6 nM, inhibits IL-β release with an IC50 of 25.3 nM.
    NLRP3-IN-61
  • HY-170530
    NLRP3-IN-62 3059965-71-5
    NLRP3-IN-62 (Compound 1) is an inhibitor for NLRP3. NLRP3-IN-62 inhibits pyroptosis in THP-1 cell with an IC50 of 0.7 nM, inhibits IL-β release with an IC50 of 108.5 nM.
    NLRP3-IN-62
  • HY-170532
    NLRP3-IN-63 3064696-02-9
    NLRP3-IN-63 (Compound 7) is an inhibitor for NLRP3, that inhibits the NLRP3 activation with an EC50 of 13 nM.
    NLRP3-IN-63
  • HY-170533
    NLRP3-IN-64 3047549-19-6
    NLRP3-IN-64 (Compound 2) is an inhibitor for NLRP3, that inhibits the NLRP3 activation with an EC50 of 5 nM.
    NLRP3-IN-64
  • HY-170535
    NLRP3-IN-65 3052859-81-8
    NLRP3-IN-65 (compound 41) is a potent NLRP3 inhibitor.
    NLRP3-IN-65
  • HY-170536
    NLRP3-IN-66 3052155-88-8
    NLRP3-IN-66 (example 257) is a potent NLRP3 inhibitor.
    NLRP3-IN-66
  • HY-170537
    NLRP3-IN-67 3055022-81-3
    NLRP3-IN-67 (compound 42) is a potent NLRP3 inhibitor.
    NLRP3-IN-67
  • HY-170540
    NOX4-IN-1
    NOX4-IN-1 (Compound 14m) is the inhibitor for NADPH oxidase 4 (NOX4), and blocks the generation of ROS. NOX4-IN-1 inhibits TGF-β1/Smad signaling pathway, decreases the expression of fibrosis-related proteins. NOX4-IN-1 inhibits the cell migration of NRK-49F.
    NOX4-IN-1
  • HY-170541
    FUT8-IN-1
    FUT8-IN-1 (Compound 37) is an inhibitor for α-1,6-fucosyltransferase (FUT8) with an KD of 49 nM and an IC50 of ca. 50 µM. FUT8-IN-1 generates a highly active naphthoquinone imine intermediate in the presence of FUT8, and inhibits the enzymatic activity of FUT8.
    FUT8-IN-1
  • HY-170543
    Dual Galectin-3/EGFR-IN-1
    Dual Galectin-3/EGFR-IN-1 (Compound 29) is the dual inhibitor for Galectin-3 and EGFR with the KD of 52.29 μM and 3.31 μM. Dual Galectin-3/EGFR-IN-1 inhibits TGF-β-induced hepatic stellate cell (HSCs) activation, induces apoptosis in LX-2 cell, and exhibits anti-liver fibrotic efficacy.
    Dual Galectin-3/EGFR-IN-1
  • HY-170544
    RIPK1-IN-28 2968509-28-4
    RIPK1-IN-28 (compound 13) is an orally active RIPK1 inhibitor. RIPK1-IN-28 inhibits human I2.1 and Hepa1‐6 cells with IC50s of 0.4 and 1.2 nM, respectively.
    RIPK1-IN-28
  • HY-170564
    PTPN22-IN-2
    PTPN22-IN-2 (Compound 8b-19) is a PTPN22 inhibitor with an IC50 of 250 nM. PTPN22-IN-2 can be used for research in the field of immunomodulation.
    PTPN22-IN-2
  • HY-170571
    BE2647
    BE2647 is a selective inhibitor for mitochondrial pyruvate carrier (MPC) with an EC50 of 70 nM. BE2647 exhibits good metabolic stability in mouse liver microsomes. BE2647 can be used in research of metabolic diseases, non-alcoholic fatty liver disease (MASLD), or non-alcoholic steatohepatitis (MASH).
    BE2647
  • HY-170579
    Antioxidant agent-20
    Antioxidant agent-20 (Compound 3d) has potent anti-inflammatory and antioxidant activity. Antioxidant agent-20 reduces reactive oxygen species (ROS) and apoptosis in a dose-dependent manner. Antioxidant agent-20 exhibits photoprotective effect against UVB-irradiated human skin keratinocytes (HaCaT) (IC50=5.13 µM) via activation of Nrf2/HO-1 signaling and inhibition of NF-κB pathway.
    Antioxidant agent-20
  • HY-170585
    COX-2-IN-51 3064260-49-4
    COX-2-IN-51 (E25) is a potent COX-2 inhibitor, with an IC50 of 70.7 nM. COX-2-IN-51 significantly inhibits LPS-induced release of NO and PGE2, expression of COX-2 and iNOS, and activation of NF-κB pathway. COX-2-IN-51 exhibits anti-inflammatory and analgesic effects in diverse murine models through inhibiting NF-κB pathway. COX-2-IN-51 has lower gastrointestinal side effects than Indomethacin (HY-14397).
    COX-2-IN-51
  • HY-170586
    JAK05
    JAK05 exhibits inhibitory activity against Helicobacter pylori, inhibits strains J63, J196 and J107 with MIC of 3-5 µg/mL. JAK05 exhibits binding affinity to H+/K+-ATPase, COX-1/2, TNF-α and PGE2, reveals antioxidant and anti-inflammatory activities. JAK05 exhibits anti-ulcer activity in rat ethanol-induced gastric ulcer models.
    JAK05
Cat. No. Product Name / Synonyms Application Reactivity